PROSPECTUS SUPPLEMENT
(To prospectus dated July 8, 1997)
[ALEXION LOGO]
Alexion Pharmaceuticals, Inc.
1,974,744 Shares of Common Stock
-----------------
This document supplements the prospectus dated July 8, 1997 relating to
the sale of 1,974,744 shares of our common stock. We are not selling any shares;
the stockholders named in the prospectus are offering their shares. This
prospectus supplement is incorporated by reference into the prospectus.
Our Nasdaq National Market Trading Symbol - ALXN
Closing Price (June 14, 1999): 10
Caduceus Capital, Ltd. and Caduceus Capital, L.P., two of the selling
stockholders named in the prospectus, have transferred their securities
portfolios to be managed and traded by a new trust, Caduceus Capital Trust. This
supplement amends the table on page 11 of the prospectus to remove Caduceus
Capital Ltd. and Caduceus Capital, L.P. as selling stockholders from the table
and to add Winchester Global Trust, as Trustee for Caduceus Capital Trust, as a
selling stockholder owning, and offering hereby, a total of 40,000 shares of our
common stock, as described on the following page.
-----------------
See "Risk Factors," which begins of page 4 of the accompanying prospectus,
for certain information that should be considered by prospective investors.
-----------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved these securities, or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
-----------------
The date of this prospectus supplement is June 15, 1999.
<PAGE>
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------
Amount of Amount of
Beneficial Beneficial
Ownership Ownership
Prior to Offering After Offering
- -----------------------------------------------------------------------------------------------------
Number of
Name of Number Percent Shares Being Number Percent
Selling Stockholder(1) of Shares(2) of Class Offered of Shares of Shares
- -----------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Winchester Global Trust, as Trustee 40,000 * 40,000 0 0
for Caduceus Capital Trust (12)
- -----------------------------------------------------------------------------------------------------
</TABLE>
- ----------
(12) Winchester Global Trust is the sole trustee of Caduceus Capital Trust.
Caduceus Capital Trust manages and trades the securities portfolios of
Caduceus Capital, L.P. and Caduceus Capital, Ltd. Caduceus Capital Trust
has sole voting and dispositive power over the shares offered hereby.
Orbimed Advisors LLC is the general partner of and financial adviser to
Caduceus Capital, L.P. and an investor in Caduceus Capital, Ltd. Samuel D.
Isaly is the managing member of Orbimed Advisors LLC. Sven Borho, Arvind
Desai, Carl Gordon and Michael Sheffery are members of Orbimed Advisors
LLC. As such, Winchester Global Trust, Caduceus Capital, L.P., Caduceus
Capital, Ltd., Orbimed Advisors LLC and Messrs. Isaly, Borho, Desai,
Gordon and Sheffery may be deemed beneficial owners of these shares.
